One method for curing or treating a disease is to discover the mechanism by which the disease occurs, and then find a way to block the mechanism, or work around it. Medical researchers discovered with narcolepsy that it is due to the malfunction of genes that stop producing orexin that is needed to regulate wakefulness and sleep. One way to cure the disease would be to fix the malfunctioning genes. Another is to find a substitute for orexin. That is the path taken by Takeda Pharmaceutical’s Orzeyful, that mimics orexin, fitting into the same receptor that ideally would receive orexin if it was present. Orexin itself cannot be effectively administered for a variety of reasons including that it has a short half-life (Ehrström et al. 2004) and has trouble crossing the blood-brain barrier (Seigneur and de Lecea 2020, 8-9).
So this is an example where first pursuing the basic science is a path to an effective treatment. Basic science is one path, but not the only path. Other paths may be more effective, or effective quicker, or at lower cost.
(p. A5) The Food and Drug Administration on Wednesday [Aug. 5, 2026] approved Takeda Pharmaceutical’s Orzeyful, the first medication to treat narcolepsy by targeting a brain chemical that regulates wakefulness. It is the first in a series of similar medications being developed by drug companies such as Eli Lilly and Alkermes that analysts say could generate more than $10 billion in sales a year.
“It’s really a complete revolution,” said Dr. Emmanuel Mignot, a sleep-medicine professor at Stanford University who led Takeda’s final studies and is credited for pioneering the science behind it. “The first time patients take it, it’s like the light switch.”
Orzeyful was approved for narcolepsy with sudden muscle weakness, a more severe form of the disorder.
Narcolepsy is unusual in neuroscience because researchers have long known exactly what causes it: A small group of brain cells that make a chemical called orexin die, disrupting a person’s ability to stay awake during the day and to sleep at night.
. . .
To study the disease, scientists at Stanford in the 1970s and 1980s used narcoleptic dogs that collapsed paralyzed when excited.
Mignot came to Stanford to study those dogs (and still owns one narcoleptic Chihuahua today). He spent about 10 years looking for the gene behind the condition and ultimately discovered that people with narcolepsy who experience sudden muscle weakness were missing the chemical orexin.
The discovery gave drugmakers a clear target in a field where most diseases involve poorly understood biology. At Japan-based Takeda, scientists searched the company’s library of chemical compounds, looking for one that could switch on the orexin receptor. In 2011, researchers discovered one that showed promise. It took several years to turn it into a pill.
For the full story see:
(Note: ellipsis, and bracketed date, added.]
(Note: the online version of this article has the date August 6, 2026, and has the title “The Race to Come Up With the Next Big Sleep Drug.”)
The academic papers I cite above are:
Ehrström, M., E. Näslund, F. Levin et al. 2004. “Pharmacokinetic Profile of Orexin a and Effects on Plasma Insulin and Glucagon in the Rat.” Regulatory Peptides 119, no. 3 (July): 209–12. https://doi.org/10.1016/j.regpep.2004.02.004.
Seigneur, Erica, and Luis de Lecea. 2020. “Hypocretin (Orexin) Replacement Therapies.” Medicine in Drug Discovery 8 https://doi.org/10.1016/j.medidd.2020.100070.
